{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:13:39Z","timestamp":1790633619851,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T00:00:00Z","timestamp":1616544000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T00:00:00Z","timestamp":1616544000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002569","name":"Wonkwang University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002569","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Oral Health"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Accurate documentation of a patient\u2019s prior medication use and awareness of side effects associated with anti-osteoporotic agents can assist dentists to prevent medication-related osteonecrosis of the jaw. I aimed to determine the awareness of Korean dentists regarding medication-related osteonecrosis of the jaw and the duration of drug holidays they prescribe to patients who need to undergo various dental procedures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      An online, questionnaire-based survey was conducted among 1000 dentists registered in an online community in Korea. The following were determined: general characteristics; type of practice; recordkeeping regarding patients\u2019 use of bone-modifying agents; requirement of a doctor\u2019s referral letter; advice given regarding drug holidays of bone-modifying agents before dental surgery procedures; and experience with medication-related osteonecrosis of the jaw. Differences between dentists with and without experience in treating patients with medication-related osteonecrosis of the jaw were evaluated using the \u03c7\n                      <jats:sup>2<\/jats:sup>\n                      test.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Although a relatively high proportion (293\/1000, 29.3%) of dentists had experienced cases of medication-related osteonecrosis of the jaw, only 650\/1000 (65.0%) routinely documented the type of bone-modifying agent used by patients and the duration of its use. Moreover, only 591\/1000 (59.1%) dentists routinely requested referral letters from doctors before performing dental surgery on patients. Although the recommended period for a drug holiday differs for each drug, 533\/1000 (53.3%) dentists did not make such a distinction. There was a statistically significant difference in the level of detail documented in terms of anti-osteoporotic drug use between dentists who had no experience in medication-related osteonecrosis of the jaw (707\/1000) and those who had such experience (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.007). There was a statistically significant difference in the length of drug holidays prescribed between dentists with and without prior experience with the condition (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These results suggest that dentists do not respond consistently to patients' drug history prior to performing dental procedures. This implies the need for increased cooperation between dentists and physicians, as well as the development of targeted educational interventions for the dental profession, to reduce the risk of medication-related osteonecrosis of the jaw.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12903-021-01475-6","type":"journal-article","created":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T13:08:05Z","timestamp":1616591285000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The awareness and practice of dentists regarding medication-related osteonecrosis of the jaw and its prevention: a cross-sectional survey"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6509-7953","authenticated-orcid":false,"given":"A. Lum","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,24]]},"reference":[{"key":"1475_CR1","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","volume":"61","author":"RE Marx","year":"2003","unstructured":"Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61:1115\u20138.","journal-title":"J Oral Maxillofac Surg"},{"key":"1475_CR2","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","volume":"72","author":"SL Ruggiero","year":"2014","unstructured":"Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw\u20142014 update. J Oral Maxillofac Surg. 2014;72:1938\u201356.","journal-title":"J Oral Maxillofac Surg"},{"key":"1475_CR3","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.joms.2006.11.003","volume":"65","author":"AT Force","year":"2007","unstructured":"Force AT. Advisory task force on bisphosphonate-related osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Associaton of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007;65:369\u201376.","journal-title":"J Oral Maxillofac Surg."},{"key":"1475_CR4","doi-asserted-by":"publisher","first-page":"731","DOI":"10.2217\/1745509X.3.6.731","volume":"3","author":"R Rizzoli","year":"2007","unstructured":"Rizzoli R, Burlet N, Cahall D, Delmas PD, Eriksen EF, Felsenberg D, et al. The impact of osteonecrosis of the jaw on osteoporosis management: executive summary of a European Society on Clinical and Economic Aspects of Osteoporosis and Foundation for Research on Osteoporosis and other Bone Diseases Working Group meeting. Aging Health. 2007;3:731\u20134.","journal-title":"Aging Health"},{"key":"1475_CR5","doi-asserted-by":"crossref","unstructured":"Malden N, Lopes V. An epidemiological study of alendronate-related osteonecrosis of the jaws. A case series from the south-east of Scotland with attention given to case definition and prevalence. J Bone Miner Metab. 2012;30:171\u201382.","DOI":"10.1007\/s00774-011-0299-z"},{"key":"1475_CR6","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.joms.2009.03.050","volume":"68","author":"JC Lo","year":"2010","unstructured":"Lo JC, O\u2019Ryan FS, Gordon NP, Yang J, Hui RL, Martin D, et al. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg. 2010;68:243\u201353.","journal-title":"J Oral Maxillofac Surg"},{"key":"1475_CR7","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/jbmr.1479","volume":"27","author":"S Papapoulos","year":"2012","unstructured":"Papapoulos S, Chapurlat R, Libanati C, Brandi ML, Brown JP, Czerwi\u0144ski E, et al. Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res. 2012;27:694\u2013701.","journal-title":"J Bone Miner Res"},{"key":"1475_CR8","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.ijom.2012.06.020","volume":"41","author":"T Yamazaki","year":"2012","unstructured":"Yamazaki T, Yamori M, Ishizaki T, Asai K, Goto K, Takahashi K, Nakayama T, Bessho K. Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates: a cohort study. Int J Oral Maxillofac Surg. 2012;41:1397.","journal-title":"Int J Oral Maxillofac Surg"},{"key":"1475_CR9","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","volume":"23","author":"F Saad","year":"2012","unstructured":"Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, Diel IJ, Takahashi S, Shore N, Henry DH, Barrios CH, Facon T, Senecal F, Fizazi K, Zhou L, Daniels A, Carri\u00e8re P, Dansey R. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded activecontrolled phase III trials in cancer patients with bone metastases. Ann Oncol. 2012;23:1341.","journal-title":"Ann Oncol"},{"key":"1475_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.maturitas.2018.11.010","volume":"120","author":"P Anagnostis","year":"2019","unstructured":"Anagnostis P, Gkekas NK, Potoupnis M, Kenanidis E, Tseridis E, Goulis DG. New therapeutic targets for osteoporosis. Maturitas. 2019;120:1\u20136.","journal-title":"Maturitas"},{"key":"1475_CR11","doi-asserted-by":"publisher","first-page":"168","DOI":"10.2478\/jim-2018-0027","volume":"3","author":"IA Albu-Stan","year":"2018","unstructured":"Albu-Stan IA, Petrovan C, Cerghizan D, Eremie LY, Cr\u0103ciun AE, Copotoiu C. Knowledge and attitude of dentists regarding patients undergoing bisphosphonate treatment: a comparative questionnaire. J Interdiscip Med. 2018;3:168\u201372.","journal-title":"J Interdiscip Med"},{"key":"1475_CR12","doi-asserted-by":"publisher","first-page":"839","DOI":"10.2147\/IJGM.S36944","volume":"6","author":"A Balasubramanian","year":"2013","unstructured":"Balasubramanian A, Brookhart MA, Goli V, Critchlow CW. Discontinuation and reinitiation patterns of osteoporosis treatment among commercially insured postmenopausal women. Int J Gen Med. 2013;6:839\u201348.","journal-title":"Int J Gen Med"},{"key":"1475_CR13","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1007\/s00198-006-0073-6","volume":"17","author":"M Rossini","year":"2006","unstructured":"Rossini M, Bianchi G, Di Munno O, Giannini S, Minisola S, Sinigaglia L, et al. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int. 2006;17:914\u201321.","journal-title":"Osteoporos Int"},{"key":"1475_CR14","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1002\/jbmr.3191","volume":"32","author":"S Hayashida","year":"2017","unstructured":"Hayashida S, Soutome S, Yanamoto S, Fujita S, Hasegawa T, Komori T, et al. Evaluation of the treatment strategies for medication-related osteonecrosis of the jaws (MRONJ) and the factors affecting treatment outcome: a multicenter retrospective study with propensity score matching analysis. J Bone Miner Res. 2017;32:2022\u20139.","journal-title":"J Bone Miner Res"},{"key":"1475_CR15","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.jcms.2014.11.014","volume":"43","author":"O Ristow","year":"2015","unstructured":"Ristow O, Otto S, Troeltzsch M, Hohlweg-Majert B, Pautke C. Treatment perspectives for medication-related osteonecrosis of the jaw (MRONJ). J Craniomaxillofac Surg. 2015;43:290\u20133.","journal-title":"J Craniomaxillofac Surg"},{"key":"1475_CR16","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s10549-010-0866-3","volume":"122","author":"V Guarneri","year":"2010","unstructured":"Guarneri V, Miles D, Robert N, Di\u00e9ras V, Glaspy J, Smith I, et al. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat. 2010;122:181\u20138.","journal-title":"Breast Cancer Res Treat"},{"key":"1475_CR17","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, Martin JS, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Eng J Med. 2009;361:756\u201365.","journal-title":"N Eng J Med"},{"key":"1475_CR18","doi-asserted-by":"publisher","first-page":"S82","DOI":"10.1016\/j.jval.2018.07.613","volume":"21","author":"G Bae","year":"2018","unstructured":"Bae G, Kwon H, An J, Park J. Cost-utility analysis of denosumab versus alendronate for postmenopausal osteoporosis in South Korea. Value Health. 2018;21:S82.","journal-title":"Value Health"},{"key":"1475_CR19","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.maturitas.2017.04.008","volume":"101","author":"P Anagnostis","year":"2017","unstructured":"Anagnostis P, Paschou SA, Mintziori G, Ceausu I, Depypere H, Lambrinoudaki I, et al. Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement. Maturitas. 2017;101:23\u201330.","journal-title":"Maturitas"},{"key":"1475_CR20","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1210\/jc.2019-00221","volume":"104","author":"R Eastell","year":"2019","unstructured":"Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2019;104:1595\u2013622.","journal-title":"J Clin Endocrinol Metab"},{"key":"1475_CR21","doi-asserted-by":"publisher","first-page":"e00127","DOI":"10.1016\/j.crwh.2019.e00127","volume":"23","author":"P Anagnostis","year":"2019","unstructured":"Anagnostis P, Paschou SA, Kenanidis E, Kenanidis E, Lambrinoudaki I, Potoupnis M, Tsiridis E, et al. \u201cHolidays\u201d for osteoporosis drugs: a case-based approach. Case Rep Womens Health. 2019;23:e00127.","journal-title":"Case Rep Womens Health"},{"key":"1475_CR22","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1002\/jbmr.3722","volume":"34","author":"S Ferrari","year":"2019","unstructured":"Ferrari S, Libanati C, Lin CJF, Brown JP, Cosman F, Czerwi\u0144ski E, et al. Relationship between bone mineral density T-score and nonvertebral fracture risk over 10 years of denosumab treatment. J Bone Miner Res. 2019;34:1033\u201340.","journal-title":"J Bone Miner Res"},{"key":"1475_CR23","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1210\/er.2004-0006","volume":"26","author":"AB Hodsman","year":"2005","unstructured":"Hodsman AB, Bauer DC, Dempster DW, Dian L, Hanley DA, Harris ST, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev. 2005;26:688\u2013703.","journal-title":"Endocr Rev"},{"key":"1475_CR24","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1007\/s00520-015-2689-6","volume":"23","author":"PB de Lima","year":"2015","unstructured":"de Lima PB, Brasil VLM, de Castro JFL, de Moraes Ramos-Perez FM, Alves FA, dos Anjos Pontual ML, et al. Knowledge and attitudes of Brazilian dental students and dentists regarding bisphosphonate-related osteonecrosis of the jaw. Support Care Cancer. 2015;23:3421\u20136.","journal-title":"Support Care Cancer"},{"key":"1475_CR25","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1111\/j.1365-2753.2009.01203.x","volume":"16","author":"P L\u00f3pez-Jornet","year":"2010","unstructured":"L\u00f3pez-Jornet P, Camacho-Alonso F, Molina-Mi\u00f1ano F, Gomez-Garcia F. Bisphosphonate-associated osteonecrosis of the jaw Knowledge and attitudes of dentists and dental students: a preliminary study. J Eval Clin Pract. 2010;16:878\u201382.","journal-title":"J Eval Clin Pract."},{"key":"1475_CR26","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/sj.bdj.2017.79","volume":"222","author":"N Tanna","year":"2017","unstructured":"Tanna N, Steel C, Stagnell S, Bailey E. Awareness of medication related osteonecrosis of the jaws (MRONJ) amongst general dental practitioners. Br Dent J. 2017;222:121\u20135.","journal-title":"Br Dent J"},{"key":"1475_CR27","first-page":"830","volume":"32","author":"MA Al Mohaya","year":"2011","unstructured":"Al Mohaya MA, Al Khashan HI, Mishriky AM, Al-Otaibi LM. Physicians\u2019 awareness of bisphosphonates-related osteonecrosis of the jaw. Saudi Med J. 2011;32:830\u20135.","journal-title":"Saudi Med J"}],"container-title":["BMC Oral Health"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12903-021-01475-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12903-021-01475-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12903-021-01475-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T13:10:14Z","timestamp":1616591414000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcoralhealth.biomedcentral.com\/articles\/10.1186\/s12903-021-01475-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,24]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1475"],"URL":"https:\/\/doi.org\/10.1186\/s12903-021-01475-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-117921\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-117921\/v2","asserted-by":"object"}]},"ISSN":["1472-6831"],"issn-type":[{"value":"1472-6831","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,24]]},"assertion":[{"value":"17 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the institutional bioethics committee of our university hospital (Wonkwang University Hospital IRB approval number: 2019-03-015) and conducted in accordance with the principles of the Declaration of Helsinki. Informed consent obtained was written from all study participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The author declares that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"155"}}